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The Role of Activated Human Platelets in Prothrombin
and Factor X Activation
By Jan Rosing, Jan L.M.L. van Rijn, Edouard M. Bevers, Gerbrand van Dieijen, Paul Comfurius, and Robert F.A. Zwaal
The effect of activated human platelets in intrinsic factor X
activation was compared with their effect in prothrombin
activation. Compared with unstimulated platelets. plate-
lets triggered by the combined action of collagen plus
thrombin showed a tenfold activity increase in prothrombin
activation, and a 20-fold rate enhancement in factor X
activation. Treatment of collagen plus thrombin-stimulated
platelets with N.naja phospholipase A2 almost completely
abolished their activity in prothrombin and factor X activa-
tion. Since no significant cell lysis occurs during phospholi-
pase treatment. this indicates that platelet phospholipids.
exposed at the membrane exterior. play an essential role in
the interaction of platelets with the proteins of the pro-
thrombin and factor X-activating complexes. The time
course of generation of the procoagulant platelet surface
was different when the amount of coagulation factors
present in the assay systems was varied. At suboptimal
concentrations of coagulation factors. maximum platelet
activity was reached after a shorter time period than at
T HE INTERACTION between blood platelets and
coagulation factors is essential for hemostatic
plug formation. Activated platelets promote the catal-
ysis of two sequential reactions of the blood coagula-
tion cascade: the activation of factor X into factor Xa
by a complex of factor IXa, factor VIlla, and Ca2￿ and
the conversion of prothrombin into thrombin by a
complex of factor Xa, factor Va, and Ca2￿ #{149}I,2
Detailed information is available on the interactions
of proteins of the prothrombinase complex with the
platelet membrane. Unstimulated bovine and human
platelets reversibly bind factor Va with high affinity.3’4
Platelet-bound factor Va, either derived from added
factor Va or released from platelets upon activation
with thrombin, is required for high-affinity factor Xa
binding.58 Kinetic experiments suggest that the plate-
let-bound factor Xa-factom Va complex participates in
prothrombin activation.
The nature of the components that comprise the
binding site for factor Va and factor Xa on the platelet
membrane is not yet defined. Similarities between the
effects of platelets and negatively charged synthetic
phospholipid vesicles in prothrombin activation led to
the assumption that negatively charged phospholipids
might also be involved in the assembly of the pro-
thrombinase complex at the platelet membrane. Neg-
atively charged (procoagulant) phospholipids are,
however, virtually absent from the outer surface of
unstimulated platelets. They are almost exclusively
located at the inner surface of the platelet plasma
membrane and in intracellular membranes.9’2 This
explains why intact unstimulated platelets show little
saturating concentrations. When measured at suboptimal
amounts of coagulation factors. the platelet activity in
prothrombin and factor X activation is also more sensitive
to phospholipase treatment. Experiments with synthetic
phospholipid mixtures show that prothrombin and factor X
activation are optimal at low mol% phosphatidylserine
when high concentrations of factor Va and factor VIlla are
employed. The optimal mol% phosphatidylserine increases
when the concentrations of nonenzymatic protein cofac-
tors are lowered. These findings are discussed in relation
to a model in which phosphatidylserine, exposed at the
outer surface of activated platelets. plays an essential role
in prothrombin and factor X activation. It is proposed that
this phosphatidylserine is not homogeneously distributed
in the platelet outer membrane. but that areas with
different phosphatidylserine density participate in coagula-
tion factor activation.
a 1985 by Grune & Stratton, Inc.
procoagulant activity compared with lysed platelets.
However, when platelets are stimulated by the com-
bined action of collagen and thrombin, about 25% of
the platelet phosphatidylserine molecules become
exposed at the platelet outer surface, presumably by a
mechanism involving transbilayer movement of phos-
phatidylserine)3”4 This process is accompanied by an
increase of activity of platelets in pmothmombin activa-
tion.
Since negatively charged phospholipids have similar
effects in factor X and prothmombin activation,’5”6 it
could be anticipated that the appearance of phosphati-
dylserine at the platelet outer surface would stimulate
both activities. In the present study, we compared the
effect of platelets, stimulated with various activators,
in prothrombin and factor X activation. We report that
those platelet activators that increase the activity of
platelets in pmothmombin activation also increase the
capacity of platelets to enhance intrinsic factor X
activation. The data support the concept that the
exposure of phosphatidylserine at the outer surface of
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platelets is essential to obtain an optimal activity of
platelets in prothmombin and factor X activation.
Materials
MATERIALS AND METHODS
52238, H-D-Phenylanalyl-L-pipecolyl-L-arginine-p-nitroanilide
hydrocholide, and 52337, N-benzoyl-L-isoleucyl-L-glutamyl-(-y-
piperidyl)-glycyl-L-arginine-p-nitroanilide hydrochloride, were pur-
chased from AB Kabi Diagnostica, Stockholm. p-Nitrophenyl-
p’-guanidinobenzoate hydrochloride (p-NPGB) was purchased from
ICN Nutritional Biochemicals (Cleveland). DEAE-Sephadex A-SO,
QAE-Sephadex A-SO, and Sephadex G-100 and G-200 were prod-
ucts of Pharmacia, Uppsala, Sweden. Factor VlII-deficient plasma
was from George King Biomedical, Overland Park, Kan. Echis
carinatus, Russell’s viper venom, soy bean trypsin inhibitor (511),
and fat-free human serum albumin were from Sigma, St Louis. Naja
naja venom was from Koch Light (Colnbrook Bucks, England).
Reaction tubes were 2-mL plastic flat-bottom tubes obtained from
Sterilin Ltd. Teddington, Middlesex, England. Tefton-coated mag-
netic spinning bars, 7 x 2 mm were purchased from Bel-Art
Products, Pequannock, NJ. Phosphatidylinositol and sphingomyelin
were purchased from Koch Light. Phosphatidylcholine ( 18: l,￿,/
l8:l￿,,-phosphatidylcholine) was from Sigma. [“C]Serotonin crc-
atine sulfate (58 Ci/mol) was obtained from Amersham Corp.
Arlington Heights, Ill. Lactate dehydrogenase reagents were from
Boehringer, Mannheim, Germany. All reagents used were of the
highest grade commercially available.
Phospholipid and Phospholipid Vesicle Preparations
Phosphatidylethanolamine and phosphatidylserine (both 18: l,￿/
18: 1,,,) were prepared from phosphatidylcholine by enzymatic syn-
thesis by the method of Comfurius and Zwaal.’7 Single bilayer
vesicle solutions were prepared according to de Kruyff,’t as
described earlier.” Phospholipid concentrations were determined by
phosphate analysis according to Bottcher et al.’9 Extraction of total
phospholipid from platelets was done according to Reed et al.￿#{176} Lipid
analysis was carried out as described previously.’3
Proteins
Phospholipase A2 was purified from Naja naja venom according
to Zwaal et al.2’ One international unit is defined as that amount of
enzyme that degrades I ￿zmol of egg phosphatidylcholine/min at
37 #{176}C. In the purified phospholipase A2, which had a specific activity
of 700 lU/mg, no proteolytic activity could be detected.2’ The
vitamin K-dependent factors, prothrombin, factor IX, and factors X,
and X2, were purified from bovine blood according to established
procedures22 as described previously.’5” The factor X activator from
Russell’s viper venom was purified as described by Schiffmann et
al.23 The purifications of thrombin, factor Xa, factor IXa, and factor
XIa (contact product) were described earlier.’5.” Bovine factor V
was purified according to a method similar to that described by Kane
et al,7 which is published in detail.24 Factor VIII:c was purified from
bovine blood according to the method of Vehar and Davie,23 with
slight modifications.2’ Factor V and factor VIII were activated with
thrombin as described earlier.2’ The specific clotting activities of the
coagulation factors were: 6 U/mg (prothrombin), 30 U/mg (factor
V), 100 U/mg (factor X), 145 U/mg (factor IX), and 324 U/mg
(factor VIII). One clotting unit is defined as the amount of coagula-
tion factor present in 1 mL normal bovine plasma. Thrombin had a
specific activity of 2360 NIH U/mg (I nmol/L thrombin is 0.085
NIH units).
Factor V was stored at -70 #{176}C in 50 mmol/L Tris, 175 mmol/L
NaCI, and 10 mmol/L CaCI2 (pH 7.9) and factor VIII in 10
mmol/L morpholino ethanesulfonic acid (MES), 175 mmol/L
NaCI, and 10 mmol/L CaCl2 adjusted to pH 6.5 with I mol/L Iris.
The other protein preparations were stored at - 70 #{176}C after dialysis
against 50 mmol/L Tris-HC1, 175 mmol/L NaCI at pH 7.9. Before
storage at -70#{176}C, prothrombin and the factor X,, X2 and IX
preparations were passed through a column of STI-agarose
(0.5 x 10 cm) to reduce the small amounts of factor Xa that might
be present in these preparations. No thrombin or factor Xa could be
detected in our protein preparations as determined with the chro-
mogenic substrates 52238 and 52337.
Protein Concentrations
Thrombin, factor Xa, and factor IXa concentrations were deter-
mined by active site titration with p-NPGB.272’ Prothrombin con-
centrations were determined after complete activation with E can-
natus venom, followed by active site titration with p-NPGB.
Similarly, factor X concentrations were obtained by active site
titration after complete activation of factors X, or X2 by RVV-X.
Factor Va concentrations were determined by kinetic analysis.2’ The
molar concentration of factor VIlla was determined by kinetic
analysis similar to that employed for factor Va.3#{176}
Isolation of Platelets
Human platelets were isolated by differential centrifugation as
described earlier.2’ Platelets were kept at room temperature in a
calcium-free buffer, pH 7.5, containing 136 mmol/L NaCl, 2.68
mmol/L KCI, 2 mmol/L MgCI2, 10 mmol/L HEPES, 5 mmol/L
glucose, and 0.05% fatty acid-free human serum albumin, conditions
at which no loss of platelet activity was found for at least I 5 hours.
Platelet concentrations were determined with a Coulter counter
(Coulter Electronics, Hialeah, Fla). Bovine platelets were isolated
according to the same procedure.
Platelet Stimulation and Determination of
Prothrombin and Factor X Converting Activity
Platelet activity in prothrombin and factor X activation was
measured in 2-mL flat-bottom plastic tubes, in which the reaction
mixtures were stirred at 350 rpm with Teflon stirring bars. To a
reaction tube containing 292.5 g￿L of a platelet suspension, I 3 giL of
75 mmol/L CaCI2 was added. The tube content was warmed and
stirred for five minutes at 37 #{176}C, and platelet activation was started
by addition of a platelet stimulator, resulting in a final volume of 325
giL and a CaCI2 concentration of 3 mmol/L. After a variable time
period at 37 #{176}C and stirring, referred to as platelet activation time,
the components for either prothrombin activation or for factor X
activation were added to determine the effect of platelets on the rates
of thrombin or factor Xa formation (see below).
Assay ofPlatelet Activity in Prothrombin Activation
Two minutes before measuring the effect of platelets in prothrom-
bin activation, 25 ML factor Va and 25 gzL factor Xa were added to
the platelet suspension to allow equilibration with the platelets.
Prothrombin activation was started by adding 125 g.tL of a
prewarmed mixture containing prothrombin in 50 mmol/L Iris-
HCI, 175 mmol/L NaCI, 14.2 mmol/L CaCl2, and 0.5 mg/mL
human serum albumin at pH 7.9. The final reaction mixture (500
giL) contained: 20 mmol/L Iris, 6 mmol/L HEPES, 150 mmol/L
NaCI, 1.6 mmol/L KCI; 2.9 mmol/L glucose, 1.2 mmol/L MgCI2, 6
mmol/L CaCI2, 0.5 mg/mL human serum albumin at pH 7.9 and
amounts of platelets, factor Xa, factor Va, and prothrombin mdi-
cated in the legends of the tables and figures. Fifteen and 30 seconds
after initiating prothrombin activation, aliquots (usually 5 or 10 ￿iL)
were taken from the reaction mixture and transferred to cuvettes to
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determine the amount of thrombin formed. The cuvettes (thermo-
stated at 37 #{176}C) contained a buffer of 50 mmol/L Tris-HCI, 175
mmol/L NaCI, 0.5 mg/mL ovalbumin, and 20 mmol/L EDTA, pH
7.9, in such amounts that the final volume was 2 mL; 335 gzmol/L of
the thrombin-specific chromogenic substrate 52238 was also pres-
ent. Further activation of prothrombin is prevented by dilution and
the presence of EDTA. The adsorbance change recorded at 405
minus 500 nm on an Aminco DW2 spectrophotometer (set in the
dual wavelength mode) is a measure of the amount of thrombin
present in the aliquots. From a calibration curve made with known
amounts of active site-titrated thrombin, determined under the same
conditions as described above, the amount ofthrombin present in the
reaction mixture is calculated. Under the conditions used, the
formation of thrombin in the reaction mixtures was linear in time,
and the rate of thrombin formation was calculated from the amount
of thrombin present after I 5 and 30 seconds.
Assay ofPlatelet Activity in Factor X Activation
Forty-five seconds before measuring the effect of platelets in
factor X activation, 25 ￿sL factor IXa and 33.4 g￿L CaC12 (60.6
mmol/L) were added to the platelet suspension. Factor X activation
was started with 16.6 ￿tL factor X2 and 100 ￿zL activated factor VIII.
The final reaction mixture (500 giL) had the same composition as
described above for prothrombin activation and contained amounts
of platelets, factor IXa, factor VIlla, and factor X indicated in the
legends of the tables and figures. Forty-five and 90 seconds after
initiating factor X activation, aliquots from the reaction mixture
were transferred to cuvettes to determine the amount of factor Xa
formed. The experimental set-up to measure factor Xa is essentially
the same as described for the measurement of thrombin formation,
with the exception that the absorbance change at 405 minus 50 nm
was measured using the factor Xa-specific chromogenic substrate
52337 (final concentration 192 ￿tmol/L). Factor Xa formation is
linear in time after a lag period of about 15 seconds after starting the
reaction. Therefore, the interval between 45 and 90 seconds after
initiating factor X activation was used to calculate the rate of factor
Xa formation. Control experiments were carried out to check
whether or not the concentration of factor Xa is adequately mea-
sured in the presence of activated platelets or artificial phospholipid
vesicles. A known amount of factor Xa was added to artificial
phospholipid vesicles plus Ca2￿ or to platelets that were subsequently
activated with thrombin plus collagen. All added factor X￿ is
recovered in the chromogenic assay described above, which indicates
that the binding of factor Xa to platelets and phospholipids is either
reversible (EDTA is present in the assay system) or does not
interfere with the chromogenic assay.
Stimulation ofPlatelets by Collagen
The collagen used in most of the experiments presented in this
article was horse tendon collagen obtained from Hormon Chemie,
MUnchen. Also, collagen prepared from bovine achilles tendon
obtained from Sigma and Merck, Germany, as well as highly
purified (type I) collagen from calfskin (a gift from Professor J.
Caen) were employed in these studies. Collagens were added in the
nonfibrillar form, dissolved in acidic dilution buffer obtained from
Hormon Chemie.
Platelet Aggregation
Platelet aggregation studies were carried out in a lumiaggregom-
eter from Chronolog Corp. Havertown, Pa. Platelets suspended in a
HEPES buffer at pH 7.5 (see above) were brought in a cylindrical
siliconized glass cuvette in a volume of 614 ￿sL and stirred with a
Teflon-coated spinning bar. This cuvette was placed in the aggre-
gometer, thermostated at 37 #{176}C, and 26 ML of a 75-mmol/L CaCI2
solution was added. The platelets were prewarmed for five minutes
and stirred. Then, 10 ￿tL platelet stimulator was added, and the
aggregation pattern was recorded.
Measurement ofSerotonin Release and Leakage of
Lactate Dehydrogenase
The conditions for platelet stimulation are the same as described
by the determination of platelet prothrombin and factor X convert-
ing activity. Release of [ “Ciserotonin was determined in the platelet
supernatant after centrifugation at 7,000 g for two minutes in an
Eppendorf microfuge. Leakage of lactate dehydrogenase was mea-
sured as described earlier.’3
RESULTS
Activity ofStimulated Platelets in Prothrombin and
Factor X Activation
In a previous article, we have shown that activation
of platelets with thrombin plus collagen resulted in the
formation of a procoagulant surface that is highly
active in pmothmombin activation.’3 It was proposed
that the exposure of the negatively charged phospholi-
pid phosphatidylserine at the outer surface of the
platelets, which accompanied the generation of the
procoagulant surface, is essential for the observed
increase of platelet activity in prothrombin activation.
In order to compare the activity of platelets in pro-
thmombin and intrinsic factor X activation, assay sys-
tems were developed in which rates of thrombin and
factor Xa formation were proportional with the
amount of pmocoagulant phospholipid present. At high
concentrations of coagulation factors, this condition
was satisfied. Figure 1A shows that with 15 nmol/L
factor Xa, 30 nmol/L factor Va, and 4 jsmol/L
prothrombin present in a reaction mixture, mates of
pmothmombin activation are proportional to the amount
of procoagulant phospholipid when a platelet lysate, a
platelet lipid extract, or synthetic vesicles, containing
2.5 or 40 mol% phosphatidylserine, are used as a
phospholipid source. At phospholipid concentrations
below 2.5 ￿tmol/L, mates of pmothrombin activation are
linear with the amount of phospholipid present. A
further increase of the concentration of coagulation
factors had no effect on the mate of thrombin forma-
tion, which indicates that all available sites on the
phospholipid surface participate in pmothrombin acti-
vation. For intrinsic factor X activation, saturation
with coagulation factors and a linear relation between
mates of factor Xa formation and the phospholipid
concentration was obtained at 150 nmol/L factor IXa,
I 5 nmol/L factor VIlla, and 0.5 ￿tmol/L factor X.
Due to a limited supply of factor VIII, it was not
possible to regularly use the saturating factor VIlla
concentrations. We succeeded, however, in selecting
coagulation factor concentrations at which rates of
factor X activation, though not saturated with respect
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Fig 1 . (A. B) Effect of the concentration of procoagulant
phospholipids on the rate of prothrombin (A) and factor X activa-
tion (B). The concentrations of phospholipid given are the final
concentrations present in the assay systems for prothrombin and
factor X activation. (-) Vesicles composed of (mol%) 2.5%
phosphatidylserine. 4% phosphatidylinositol. 47.5% phosphatidyl-
choline, 28% phosphatidylethanolamine. 18% sphingomyelin. and
cholesterol in a 1 :1 molar ratio to total phospholipid. (A-A)
Vesicles composed of 40% phosphatidylserine. 4% phosphatidyl-
inositol. 10% phosphatidylcholine. 28% phosphatidylethanolam-
inc. 1 8% sphingomyelin. and cholesterol in a 1 :1 molar ratio to
total phospholipid. (S-U) Vesicles made from a total phospholipid
extract from platelets. (A-A) Sonicated platelets. Prothrombin
activation was measured at 4 gimol/L prothrombin, 15 nmol/L
factor Xa. and 30 nmol/L factor Va and factor X activation at 0.5
gimol/L factor X. 50 nmol/L factor IXa and 0.1 nmol/L factor VIlla.
The total lipid extract from platelets had the following phospholi-
pid composition: 1 1 % phosphatidylserine. 4% phosphatidylinositol.
39% phosphatidylcholine. 28% phosphatidylethanolamine. 18%
sphingomyelin. and cholesterol in a 1 :1 molar ratio to phospholipid.
Lipid extraction from platelets. lipid analysis. and the assay
systems for prothrombin and factor X activation are described in
Materials and Methods.
to factor VIlla, are still proportional with the amount
of phospholipid present (Fig 1B).
Table 1 shows the effect of human platelets, stimu-
lated with various platelet activators, in prothrombin
and factor X activation. Human platelets (5 x 106
platelets/mL), stimulated for 15 minutes with optimal
concentrations of different platelet activators, were
used as a source of phospholipid in the assay systems
described above. In this experiment, factor X activa-
tion is measured at saturating factor VIlla concentra-
tions (15 nmol/L). Release of semotonin and platelet
aggregation was determined in a separate experiment.
Platelets stimulated by the combined action of 10
￿sg/mL collagen and 1.3 nmol/L thrombin exhibited a
tenfold activity increase in pmothrombin activation and
were 20 times more active in factor X activation than
unstimulated platelets. Platelets stimulated only with
thrombin show little rise in activity, but platelet stimu-
lation with collagen alone resulted in activities that
were approximately 30% of that observed with plate-
lets stimulated by collagen plus thmombin. In a recent
article, Bevems et al’￿ have shown that there is a limited
exposure of phosphatidylserine when platelets are
stimulated with collagen alone. Although the standard
deviation for the determination of the amount of
phosphatidylserine exposed was relatively high, it is
possible that it accounts for the procoagulant activity
observed for collagen-stimulated platelets. However, it
can also not be ruled out that activities found with
collagen-stimulated platelets were in fact the result of
a combined action of collagen and small amounts of
thrombin present in the assay system. In the pmothmom-
binase assay, 2 nmol/L thrombin is formed in less than
five seconds, while thrombin is also present in the assay
system in which factor X activation is measured,
because the factor Villa preparation still contained
the small amounts of thmombin that were used for the
activation of factor VIII. With other platelet activators
(adenosine diphosphate, serotonin, epinephrine, either
alone or in combination), activities similar to unstimu-
lated platelets were observed (data not shown). It is
essential that platelets are stirred during the activation
process. Nonstirred platelets incubated with thrombin
plus collagen show no activity increase in prothrombin
and factor X activation. It should be emphasized that
the prothmombin and factor X converting activities
mainly reside with the stimulated platelets, since less
than 10% of the activity remained in the supemnatant
after sedimenting the platelets by centrifugation at
7,000 g.
A possible explanation for the effect ofcollagen plus
thrombin could be that platelets stimulated with this
trigger are subject to increased cell lysis. This could
explain the increased prothrombin and factor X con-
verting activities, since lysed platelets are highly active
in prothrombin and factor X activation (Fig 1A and
B). We used leakage of lactate dehydmogenase, a
cytoplasmic platelet enzyme, as a marker for cell Iysis
during platelet activation. Approximately 1% to 2% of
the total lactate dehydmogenase present leaks out of
platelets that were stimulated with thmombin or col-
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Table 1 . Effect of Platelets in Prothrombin and Intrinsic Factor X Activation:
A Comparison With Platelet Aggregation and Serotonin Release
Prothrombin Factor X
Activation
(nmol/L Ila/min) (n
Activation
mol/L Xa/min)
Seroton,n
Release
Platelet St,mulator Xa Xa-Vat lXa￿ lXa-Vllla￿ Ag￿egation (%)
None 0 34.4 <0.1 2.3 - 0
Thrombin 1.9 40.3 <0.1 3.1 + 72
Collagen 7.9 98.7 <0.1 18.6 + 60
Thrombin + collagen 24.5 35 1.5 <0. 1 47.3 + 74
Thrombin + collagen + phospholipase A2 0.4 17.4 <0. 1 1 . 1 ND ND
ND. not determined.
0.5 nmol/L factor Xa, no factor Va, 4 gimol/L prothrombin.
t 1 5 nmol/L factor Xa, 30 nmol/L factor Va, 4 ￿smol/L prothrombin.
￿ 1 50 nmol/L factor IXa, no factor VIlla, 0.5 ￿tmol/L factor X.
§ 1 50 nmol/L factor IXa, 1 5 nmol/L factor VIlla, 0.5 gimol/L factor X.
Human platelets at a concentration of 5 x 106/mL were stimulated for 15 minutes with 1.3 nmol/L thrombin and/or 10 gzg/mL collagen. In the
experiment in which phospholipase was used, platelet stimulation was followed by a 15-minute incubation with 3 IU/mL phospholipase A2 (Naja naja).
Platelet aggregation was measured in a separate experiment at 5 x 1O￿ platelets/mL. Platelet aggregation, serotonin release, and rates of prothrombin
and factor X activation were determined as described in Materials and Methods.
lagen plus thrombin. The mates of pmothrombin and
factor X activation for a preparation of 2% lysed
platelets, either obtained by I :50 dilution of completely
lysed platelets or by limited sonication that liberated
2% of the lactate dehydmogenase present in platelets,26
were 58 nmol/L thrombin/min and 3.8 nmol/L factor
Xa/min, respectively. Since this is far below the mates
observed with collagen plus thrombin stimulated plate-
lets, we conclude that the increased activity of these
platelets is not due to cell lysis.
To stress the importance of the presence of added
nonenzymatic cofactors, factors Va and factor Villa
experiments are included in Table 1 , in which the
activity of stimulated platelets in pmothrombin and
factor X activation is measured in the absence of added
factor Va or factor Villa. The presence ofadded factor
Villa is essential to observe activity of collagen plus
thrombin stimulated platelets in factor X activation.
This indicates that there is no release of factor VIII:c
from stimulated platelets. The lack of activity of
platelet lysates (up to iO￿ lysed platelets/mL) in factor
X activation measured in the absence of factor Villa
suggests that platelets do not contain detectable
amounts of factor VIII:c. The activity of thrombin and
collagen plus thrombin stimulated platelets in pro-
thmombin activation, measured in the absence of added
factor Va is presumably enhanced by factor V liber-
ated from the platelets during the release reaction.
Also, in the absence of added factor Va, platelets
stimulated with collagen plus thrombin had the highest
activity in pmothmombin activation.
To test the proposal that the procoagulant surface of
activated platelets has a “phospholipid-like” nature,
platelets were first stimulated with collagen plus
thrombin and subsequently treated with Naja naja
phospholipase A2, an enzyme able to degrade phos-
pholipid molecules exposed at the outer platelet sum-
face.’33’ Under these conditions, both the prothmombin
and factor X converting activities were almost corn-
pletely abolished, and activities were observed that
were even below those of unstimulated platelets (Table
I ). The activity of unstirnulated platelets is also dmasti-
cally lowered upon treatment with phospholipase A2.3’
The absence of leakage of lactate dehydrogenase from
the platelets indicates that the platelet membrane
remains intact during treatment with phospholipase
A,.
The experiment presented in Table 1 was also
carried out with bovine platelets. The effects of throm-
bin, collagen, and collagen plus thrombin on the pro-
thmombin and factor X converting activities of bovine
platelets were the same as on human platelets.
Dependence ofPlatelet Activation on the
Concentration of Thrombin, Collagen. and the
Source of Collagen
The activity of platelets in prothrombin and factor X
activation was measured after stimulation with van-
able amounts of collagen, either in the absence of
thrombin or at a constant thrombin concentration (5
nmol/L). As shown in Fig 2, both activities rise
parallel when the amount of collagen is increased and
reach a maximum at a collagen concentration of 8
sg/mL. The collagen used in this experiment was in
the nonfibmillam form. When collagen was first allowed
to form fibmils at neutral pH and subsequently used for
platelet stimulation, the same activity in prothrombin
and factor X activation was found. The collagen was
obtained from horse tendon (Hommon Chemie). Col-
lagens prepared from bovine achilles tendon (Sigma
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Fig 2. Stimulatory effect of varying amounts of collagen.
either in the absence or presence of thrombin, on the activity of
platelets in prothrombin and factor X activation. Platelets
(0.9 x 107/mU were stimulated for ten minutes with 0 to 40
gig/mi collagen (open symbols) or 5 nmol/L thrombin plus 0 to 40
gig/mi collagen (closed symbols). Prothrombin (￿-￿) and factor
x (0-a) activation were determined as described in Materials and
Methods. The concentrations of coagulation factors present in the
assay systems were: 4 gimol/L prothrombin, 15 nmol/L factor Xa.
and 30 nmol/i factor Va (prothrombin activation) or 0.5 gimol/i
factor X, 50 nmol/L factor IXa, and 0.1 nmol/L factor VIlla (factor
x activation). One hundred percent activity in prothrombin activa-
tion was 670 nmol/L Ila/min and in factor X activation 1 5.1 nmol/L
Xa/min.
and Merck) and a highly purified type I collagen from
calfskin are equally active in generating platelet pro-
thrombin and factor X converting activities (data not
shown).
The effect of variable thmornbin concentrations is
shown in Fig 3. In the presence of 4 jsg/mL collagen,
0.1 nmol/L thmombin is already sufficient to evoke
maximal platelet activity in prothrombin and factor X
activation. In the absence of collagen, there is a slow
rise of both activities when the amount of thrombin is
increased. At high thrombin concentrations, the plate-
let activity is still appreciably lower than that of
platelets stimulated by the combined action of throm-
bin plus collagen.
The concentrations of thrombin and collagen
required to expose the procoagulant surface are similar
to those required to induce platelet aggregation and
release. Table 2 summarizes the concentrations of
thrornbin or collagen that produce threshold, half-
maximal, and maximal effects in platelet aggregation
and release. The combined effect of thrombin plus
collagen on these platelet functions is synergistic.
Combination of concentrations of collagen and throm-
bin below the threshold concentrations for the individ-
ual components already produce half-maximal platelet
aggregation and release.
Time Course ofAppearance ofPlatelet Activity in
Prothrombin and Factor X Activation
The generation of a procoagulant surface was fol-
lowed in time for platelets stimulated with thrombin or
/-L-
--- . I 20
thrombin ( nM)
Fig 3. Stimulatory effect of varying thrombin concentrations
on the activity of platelets in prothrombin and factor X activation.
Platelets (0.9 x 107/mi) were stimulated for ten minutes with
varying concentrations of thrombin in the absence (open symbols)
and presence of 4 gig/mi collagen (closed symbols). The concen-
tration of thrombin given in this figure is nmol/L present in the
platelet activation mixture (1 nmol/L thrombin is approximately
0.085 NIH U thrombin). Prothrombin (A-A. ￿-￿) and factor X
(#{149}-#{149}. 0-0) activation was determined as described in Materials
and Methods. The concentrations of coagulation factors in the
assay systems were 4 gimol/i prothrombin. 15 nmol/L factor Xa.
30 nmol/L factor Va (prothrombin activation) or 0.5 gsmol/L factor
x. so nmol/i factor lXa 0.1 nmol/L factor VIlla (factor X activa-
tion). One hundred percent activity in prothrombin activation was
600 nmol/L Ila/min and in factor X activation 16.6 nmol/L Xa/
mm.
with collagen plus thrombin. Since the effect of col-
lagen alone could not be singled out from the combined
collagen and thrombin effect (see above), collagen-
stimulated platelets were not further considered. The
activity of platelets in prothmombin activation was
measured with different concentrations of factor Xa
and factor Va present in the prothrombinase assay.
The pmothrornbin activating mixtures contained plate-
lets, 4 smol/L pmothrombin, and 0.5 nrnol/L factor
Xa; no added factor Va (Fig 4A), 0.5 nmol/L factor
Xa, 1 nmol/L factor Va (Fig 4B); or I 5 nmol/L factor
Xa, 30 nmol/L factor Va (Fig 4C). In all assay
systems, platelets became active upon stimulation with
collagen plus thrombin. As expected, the highest activ-
ities were found at saturating factor Xa and factor Va
concentrations (Fig 4C). Unstimulated platelets
exhibited the lowest prothrombin converting activity.
Table 2. Collagen and Thrombin Requirements for
Aggregation and Release
Platelet
Aggregation/Release
Threshold Half-Max,mal
Platelet Act,vator Effect Effect
Maximal
Effect
Thrombin 0.5 nmol/L 0.75 nmol/L
Collagen 1 .0 ￿zg/mL 3.3 gzg/mL
Thrombin plus collagen 0.4 nmol/L plus
0.5 gzg/mL
1.2 nmol/L
5.0 ￿sg/mL
Platelets were activated by thrombin and/or collagen at a concentra-
tion of 5 x 10￿ platelets/mL, and the platelet aggregation and release
reaction was measured as described in Materials and Methods.
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Fig 4. (A through D) Time course of appearance of platelet
activity in prothrombin and factor X activation. The platelet
concentration during stimulation was 0.9 x 107/mL. Platelets
were not stimulated ￿ stimulated with 1 .3 nmol/ I thrombin
(A-A). or stimulated with 1 .3 nmol/L thrombin plus 10 gig/mi
collagen (-). At different time intervals after stimulation.
coagulation factors were added and prothrombmn (A. B, C) and
factor X (D) activation were measured as described in Materials
and Methods. The amounts of coagulation factors present in the
assay systems were: (A) 4 gimol/i prothrombin. 0.5 nmol/i factor
Xa, no factor Va; (B) 4 gimol/L prothrombin. 0.5 nmol/i factor Xa.
1 .0 nmol/L factor Va; (C) 4 gimol/L prothrombin. 1 5 nmol/L factor
Xa, 30 nmol/i factor Va; or (D) 0.5 gimol/i factor X. 50 nmol/i
factor IXa, and 0.1 nmol/L factor VIlla.
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Stimulation of platelets with thrombin alone resulted
in a slow rise of pmothrombin converting activity when
added factor Va is present in the prothmombinase assay
mixture (Fig 4B and C). When prothrombin activa-
tion is measured in the absence of added factor Va, the
situation is somewhat different (Fig 4A). Unstimu-
lated platelets are completely inactive in pmothrornbin
activation, presumably due to the virtual absence of
both a procoagulant surface and factor Va. Thmombin
stimulation of platelets gives rise to an appreciable
activity of platelets in pmothrombin activation when
this is measured in the absence of added factor Va and
compared with the activity of unstimulated platelets.
However, also in the absence of added factor Va, the
highest activity was observed with platelets stimulated
by thrombin plus collagen. We propose that in platelet
experiments carried out in the presence of a saturating
concentration factor Va, the mate of prothrombin acti-
vation is determined by the procoagulant surface
already present in the case of unstimulated platelets or
the procoagulant surface generated in case of platelets
stimulated with thmombin plus collagen. In the absence
of added factor Va, both the presence or appearance of
the procoagulant surface and the release of platelet
factor Va is probed. We have no explanation for the
origin of the procoagulant surface of unstimulated
platelets. It is either present on platelets circulating in
the blood or exposed upon platelet lysis or platelet
activation during venipunctume of the blood or the
isolation of the platelets.
The platelet pmocoagulant activity increases rapidly,
without a lag period, directly upon activation. We have
extended our measurements over a period of 15 to 30
minutes to determine the maximal prothrombin and
factor X converting activities that can be reached in
order to calculate and compare the maximal number of
pmocoagulant sites that can be exposed (see Discussion
and Table 4, below). It should be emphasized, how-
ever, that two minutes after platelet activation by
thrombin plus collagen the prothrombin converting
activity has already risen to 100 nmol/L thrombin
fommed/min/6.6 x 106 platelets/mL (Fig 4B and C).
Taking into account that the amount of platelets in
whole blood is 2 x l08/mL and that the plasma
prothmombin concentration is approximately 2,000
nmol/L, it is obvious that the platelet pmothrornbin
converting activity reached after two minutes would be
more than sufficient to account for in vivo thrombin
formation.
One other feature of the time generation curves has
to be mentioned here. The appearance of platelet
prothrombin converting activity is apparently more
rapid when prothrombinase activity is assayed in a
system containing low amounts of factor Xa and factor
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Va. Half-maximal activities were obtained after 2’/2
minutes (Fig 4A), four minutes (Fig 4B), and nine
minutes (Fig 4C). Compared with prothmombin con-
verting activity, factor X converting activity appeared
even more rapidly when platelets were stimulated by
thrombin plus collagen (Fig 4D). Within two minutes
after platelet activation, half-maximal factor X con-
venting activity was observed in an assay system, in
which suboptimal factor VIII concentrations were
used. Also, in factor X activation, unstimulated plate-
lets exhibit a constant and low activity, and stimulation
with thrombin alone results in a slow rise of platelet
activity.
The effect of platelet concentration in prothmombin
and factor X activation is shown in Fig SA and B.
Collagen plus thrombin stimulated platelets show a
linear increase of both activities with the platelet
concentration, until mates of thrombin and factor Xa
formation were reached at which clotting factor acti-
vation in these assay systems is no longer linearly
proportional to the amount of phospholipid present (cf,
‘r#{176}#{176}
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Fig 5. (A and B) Effect of the concentration of stimulated
platelets on the rates of prothrombin and factor X activation.
Platelet stimulation and the assay systems for prothrombin activa-
tion (A) and factor X activation (B) are described in Materials and
Methods. Platelets were not stimulated (-U). stimulated for 15
minutes with 1 .3 nmol/i thrombin (A-A). or stimulated for 15
minutes with 1 .3 nmol/L thrombin plus 10 gig/mi collagen (I-S)
Prothrombin activation was measured at 4 gimol/L prothrombin,
1 5 nmol/i factor Xa, 30 nmol/L factor Va (A). Factor X activation
was measured at 0.5 gimol/i factor X, 50 nmol/i factor lXa. and
0.1 nmol/L factor Villa (B). The amount of platelets indicated in the
figure is that present in the final assay mixture.
Fig 1). Thrombin-stimulated and -unstimulated plate-
lets also show a linear increase of factor X activation
when the platelet concentration in the assay system is
increased. For the slight deviation from linearity with
thrombin-stimulated platelets at high platelet concen-
trations, we have no explanation.
Effect ofPhospholipase A2 on the Activity of
Stimulated Platelets in Prothrombin and
Factor X Activation
The results presented in Table 1 show that the
activity of platelets in pmothrombin and factor X
activation could be completely abolished by treating
the collagen plus thrombin stimulated platelets with
phospholipase A2. The time course of disappearance of
platetet pmothmombin and factor X converting activities
was followed when platelets stimulated for 30 minutes
with thrombin plus collagen were subsequently treated
with a small amount of phospholipase A2 (0.04 IU/
mL). After different time intervals of phospholipase
treatment, coagulation factors were added to measure
the remaining activity of platelets in pmothrombin and
factor X activation. Figure 6 shows that the pmothrom-
binase activity of stimulated platelets is more sensitive
to phospholipase treatment when measured in the
absence of factor Va than at suboptimal and saturating
factor Xa and factor Va concentrations. It seems that
Fig 6. Effect of phospholipase A2 on the activity of stimulated
platelets in prothrombin and factor X activation. Platelets
(0.9 x 107/mL) were stimulated for 30 minutes with 1.3 nmol/i
thrombin plus 10 gig/mi collagen. Then. phospholipase A2 was
added to a final concentration of 0.04 lU/mi. After the time
intervals indicated, the remaining activity of platelets in prothrom-
bin and factor X activation was measured as described in Materials
and Methods. Prothrombin activation was determined at: 4 gimol/
I prothrombin. 0.5 nmol/i factor Xa, no added factor Va (A-A); 4
gimol/i prothrombin. 0.5 nmol/L factor Xa. 1 nmol/L factor Va
(S-U); 4 gimol/i prothrombin. 1 5 nmol/i factor Xa. and 30 nmol/i
factor Va (S-S). Factor X activation was measured at 0.5 gimol/L
factor X, 50 nmol/i factor IXa. and 0.1 nmol/L factor Villa (0-0).
Rates obtained with 30-minute stimulated platelets. set at 100%.
were, respectively. 750 nmol/L ha/mm, 423 nmol/i ha/mm. 44.2
nmol/i ha/mm, and 18.5 nmol/i Xa/min. When no phospholipase
was added. the activity of the platelets remained virtually con-
stant. The dotted line represents the effect of the extra addition of
2 lU/mi phospholipase A2.
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Prothromb,n Factor X Serotonin
Activation Activation Release
Platelet Stimulator (nmol/L lla/m,n) (nmol/L Xa/min) Aggregation (%)
Nontreated platelets
None 46.0 0.42 - 0
Thrombin 50.2 0.60 + 69
Thrombin plus collagen 385.4 9.45 + 72
Phospholipase A2-treated platelets
None 16.2 <0.1 - 0
Thrombin 23.4 <0. 1 + 65
Thrombin plus collagen 297.6 7.8 + 75
Human platelets at a concentration of 5 x 108/mL were incubated at 37 #{176}C for 70 minutes with 3 mmol/L CaCI2. in either the absence or presence of
0. 1 IU/mL phospholipase A2 (Naja naja). After treatment. the platelets were diluted to 5 x 1O7/mL (for measurement of platelet aggregation and release)
or 5 x 106/mL (for measurement of their procoagulant properties). The diluted platelet suspensions were stimulated for 15 minutes with 1.3 nmoi/L
thrombin and/or 10 zg/mL collagen. The prothrombin and factor X converting activities were measured as described in Materials and Methods at 15
nmol/L factor Xa, 30 nmol/L factor Va, 4 gimol/L prothrombin. and 50 nmol/L factor IXa, 0. 1 nmol/L factor VIlla. and 0.5 gimol/L factor X,
respectively.
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part of the pmothmombinase activity measured at satu-
mating factor Xa and factor Va is less sensitive to
phospholipase treatment. The pmothrombinase activity
measured at saturating factor Xa and factor Va could,
however, be completely abolished when the stimulated
platelets were treated with higher amounts of phos-
pholipase A2 (2 IU/mL). Figure 6 also shows that the
factor X converting activity of stimulated platelets
measured at suboptimal factor Villa is highly sensitive
to treatment with low amounts of phospholipase A2.
The results shown in Fig 6 cannot be due to a
detrimental effect of phospholipase A2 on the coagula-
tion factors, since their activity was not affected by
prolonged incubation with phospholipase. This can
actually also be concluded from the experiment itself.
For each data point in the figure, there is an equal time
of incubation of coagulation factors with phospholi-
pase A2. This enzyme is added at time 0 (after activa-
tion of platelets for 30 minutes with thrombin plus
collagen), and the coagulation factors are added at 2,
4, 6, 8, 10, or 15 minutes to probe the remaining
procoagulant surface. Also, the fact that after proper
dilution phospholipase-treated control platelets still
become active in pmothrombin and factor X activation
and show a normal response in aggregation and release
upon stimulation with thrombin and/or collagen dem-
onstrates that the action of phospholipase A2 is
restricted to phospholipids exposed at the membrane
exterior (Table 3). Platelet aggregation and release are
even not affected when control platelets are treated at
a ten-fold higher phospholipase A2 concentration.
In our laboratory, we confirmed the finding of
Verhey et al32 that the degradation products of phos-
pholipases (lysophospholipids) do not interfere with
coagulation factor activation and are therefore not
anticoagulant. Membrane bilayers composed of lyso-
phosphatidylsemine and lysophosphatidylcholine plus
the appropriate fatty acids neither stimulate nor
inhibit pmothrombin activation. The abolishment of the
prothrombin and factor X converting activities of
thrombin plus collagen stimulated platelets upon treat-
ment with phospholipases is therefore indicative for a
“phospholipid-like” nature of the pmocoagulant sum-
face.
Effect ofDifferent Synthetic Phospholipid Mixtures
in Prothrombin and Factor X Activation
It was investigated whether differences in time
course of generation of a procoagulant platelet surface
probed at varying coagulation factor concentrations
and the accompanying different sensitivities to phos-
pholipase A2 treatment could be related to differences
in phospholipid requirement. Therefore, prothrombin
and factor X activation were measured in the presence
of phospholipid vesicles with varying lipid composition.
These vesicles were composed of lipids present in
platelet membranes. The mole fraction of each phos-
pholipid was fixed at the same value as found in a total
lipid extract of platelets, with the exception of phos-
phatidylsenine and phosphatidylcholine. Pmothrombin
activation was measured in the absence of factor Va
and at the suboptimal and saturating factor Xa and
factor Va concentrations also employed in Fig 4.
Factor X activation was measured in the absence of
factor Villa and at the same coagulation factor con-
centmations as used in Fig 4D.
Large differences between pmothmombin and factor
X activation at different coagulation factor concentra-
tions were observed when the mole fraction phosphati-
dylsenine in a vesicle was varied at the expense of
￿phosphatidylcholine (Fig 7A and B). The mole frac-
tion phosphatidylsenine required for maximal stimula-
tion of prothmombin and factor X activation varied at
different coagulation factor concentrations. In pro-
thrombin activation, the optimal phosphatidylsemine
mole fraction varied from 2.5 mol% at saturating
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Fig 7. (A and B) The effect of phospholipid vesicles with
varying mole percentage phosphatidylserine in prothrombin and
factor X activation. The phospholipid composition of the vesicles
in mol% of total phospholipid was: 28% phosphatidylethanolamine.
19.6% sphingomyelin. phosphatidylserine as indicated in the fig-
ure, supplemented to 100% with phosphatidylcholine. Cholesterol
was present in a 1 :1 molar ratio to total phospholipid. The
preparation of vesicles and the assay systems for prothrombin and
factor X activation are described in Materials and Methods. (A)
Prothrombin activation: (A-A) 2 gimoi/i phospholipid, 4 gimol/i
prothrombin, 1 5 nmol/L factor Xa. no factor Va. 100% = 4.2
nmol/i Ila/min; (#{149}-#{149}) 2 gimol/i phospholipid. gimol/i prothrom-
bin, 0.5 nmol/i factor Xa. 1 nmol/L factor Va. 100% = 803 nmol/i
ha/mm; (#{149}￿-S) 2 gimol/i phospholipid. 4 gimol/L prothrombin. 15
nmol/i factor Xa, 30 nmol/i factor Va, 100% = 2,900 nmol/i
ha/mm. (B) Factor X activation: (A-A) 25 gimol/L phospholipid,
0.5 gimol/L factor X. 50 nmol/i factor IXa. no factor Villa, 100% =
1.5 nmoi/L Xa/min; (0-0) 2 gimoi/i phospholipid. 0.5 gimol/i
factor X. 50 nmol/L factor IXa, 0.1 nmol/i factor VIII. 100% = 71.5
nmol/i Xe/mm; (D-D) 2 gimol/i phospholipid. 0.5 gimol/i factor
x, 150 nmol/i factor IXa, 15 nmol/i factor Villa. 100% = 250
nmoi/L Xa/min.
factor Xa and factor Va concentrations to more than
40 mol% when pmothmombin activation was measured
in the absence of factor Va (Fig 7A). Phospholipid
vesicles with more than 40 mol% phosphatidylsenine
were not used in this experiment because they aggre-
gate in the presence of 10 mmol/L CaCl2. For factor X
activation, the same phenomenon was observed. The
phosphatidylsenine optimum was dependent on the
amounts of factor IXa and factor Villa present in the
assay system for factor X activation (Fig 7B). At high
concentrations of factor IXa and factor Villa, the
optimum is observed at 10 mol% phosphatidylsenine,
while similar to pmothrombinase, the optimum in the
absence ofthe nonenzymatic cofactor factor VIlla is at
40 mol% phosphatidylsemine or higher. These differ-
ences in phosphatidylserine requirement at different
coagulation factor concentrations can explain the
observed differences in time course of generation of a
procoagulant platelet surface and sensitivity to phos-
pholipase treatment measured under the same condi-
tions (see Discussion).
DISCUSSION
The experiments presented in this article show that
platelets stimulated with thrombin plus collagen
expose a procoagulant surface that highly promotes
pmothrombin and intrinsic factor X activation. With
unstimulated and thrombin-stimulated platelets,
markedly lower activities were observed. In previous
articles,’3’4 we have shown that the negatively charged
phospholipid phosphatidylserine, which is localized in
unstimulated platelets in the inner membrane mono-
layer, becomes exposed in the outer membrane mono-
layer when platelets are activated with collagen plus
thmombin . Negatively charged phospholipids are
required in synthetic phospholipid vesicles that are
used as a procoagulant surface in prothrombin and
factor X activation. We therefore propose that the
phosphatidylsemine exposed at the outer surface of
activated platelets plays an important role in the
interactions of the platelet membrane with the proteins
of the prothrombin and factor X activating complexes
and that these interactions are essential for the
observed mate enhancements of prothrombin and factor
X activation. This concept is supported by the finding
that the activity of stimulated platelets in prothmombin
and factor X activation is almost completely abolished
when the collagen plus thmombin stimulated platelets
are treated with phospholipase A2 (Table 1). In this
experiment, phospholipase action was limited to phos-
pholipids of the outer membrane monolayer, and the
membrane integrity was left intact.
Our experiments do not rule out an involvement of
platelet membrane proteins in the interactions with the
coagulation factors. Majerus and coworkers33 de-
scnibed a patient with a bleeding disorder whose plate-
lets lack a surface component required for the binding
of the factor Xa-Va complex. In a recent paper,4 they
proposed that this component presumably is a protein.
The group of Mann reported that unstimulated bovine
platelets bind factor Va three orders of magnitude
tighter than synthetic phospholipid vesicles.3 Although
“a highly specialized phospholipid structure” at the
platelet surface can cause this affinity difference, it
can also be visualized that a platelet membrane protein
is responsible for this phenomenon. Tuszynski et al34
demonstrated that platelet-bound factor Va is asso-
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ciated with components from the platelet cytoskeleton.
The ability of the cytoskeleton to promote factor
Xa-catalyzed pmothrombin activation is, however, still
dependent on the presence of lipid. Our experiments
were designed in such a way that mates of prothrombin
and factor X activation are limited by the availability
of a negatively charged procoagulant phospholipid
surface. Saturating coagulation factor concentrations
were employed so that the binding affinities of the
membrane for the coagulation factors became less
important. Therefore, we cannot rule out the possibil-
ity that besides phosphatidylsemine, other membrane
components play a mole in the assembly of the pro-
thmombin and factor X activating complexes at the
surface of platelets stimulated with collagen plus
thrombin.
Kinetic experiments have shown that the activation
of pmothmombin and factor X in the absence of phos-
pholipids is a very inefficient process.’5’6 Phospholipids
dramatically stimulate these reactions because they
promote the assembly of the prothrombin and factor X
activating complexes in such a way that phospholipid-
bound substrates (pmothmombin or factor X) are acti-
vated by phospholipid-bound enzymes (factor Xa-Va
or factor IXa-VIIIa). In experiments with thrombin
plus collagen stimulated platelets, such high mates of
pmothmombin and factor X activation were observed
that it seems justified to assume that the activation of
coagulation factors takes place at the platelet mem-
brane surface. This would mean that in analogy with
the model system,’5’6 platelet-bound prothrombin and
factor X are activated by a platelet-bound factor
Xa-Va and factor IXa-VIIIa complex, respectively.
Binding of prothmombin to the platelet membrane,
however, has not yet been demonstrated. Ifthe binding
affinity of platelets for pmothrombin is similar to that of
synthetic phospholipids, it is possible that it escaped
detection because the affinity would then be three to
four orders of magnitude lower than observed for
factor Xa and Va.
Both bovine and human platelets possess high-
affinity binding sites for factor Va.34 Some I ,000 to
2,000 binding sites with an approximate Kd of l0l0
mol/L are detected per platelet, independent of
whether or not the platelets are stimulated with throm-
bin. Platelet-bound factor Va is the receptor for factor
Xa. Two hundred to 300 binding sites for factor Xa are
present per platelet either from human5 or bovine
sources.36 In these studies, there was no investigation
of platelets stimulated with collagen plus thrombin.
The platelet-bound factor Xa participates in pro-
thrombin activation. From reports of other labomato-
mies, it can be calculated that thrombin-stimulated
human5 and bovine platelets,35 in which factor V
released from platelets is the source of factor Va,
activate pmothmombin at a rate of 4 to 8 nmol/L
thmombin formed per minute with l0￿ platelets/mL.
This correlates very well with the 1.9 nmol/L thrombin
formed per minute that we observed with 0.3 x l0￿
thrombin-stimulated platelets/mL when we measured
pmothmombin activation in the absence of added factor
Va (Table 1 ). Platelets have, however, a much higher
capacity to promote pmothmombin activation. Table I
also shows that platelets stimulated with collagen plus
thrombin exhibit a 170-fold higher activity. In this
experiment, saturating amounts of factor Xa and
factor Va were present. It is essential that a limited
amount of platelets is used in these experiments. At
high platelet concentrations (5 x 107/mL), such a
large number of pmocoagulant sites is exposed that even
if enough factor Xa and factor Va could be added to
saturate these sites, the pmothmombin available in the
assay systems would be completely converted within a
few seconds. It should also be emphasized that plate-
lets have to be stirred during stimulation in order to
obtain procoagulant activity. Stirring of platelets is
also essential for the expression of other platelet func-
tions. Nonstimmed platelets activated with the proper
stimuli do not aggregate. Also, the release of serotonin
is drastically diminished or even absent if nonstimmed
platelets are activated with collagen,2 adenosine
diphosphate (ADP),36 or the ionophore A23 I ￿ We
have ruled out possible artifacts like platelet lysis and
platelet fragmentation. Activation of stirred platelets
with thrombin plus collagen does not induce liberation
of cytoplasmic lactate dehydrogenase, and fragmenta-
tion of platelets is unlikely because more than 90% of
the procoagulant activity sediments with platelets
upon centrifugation. We do not know why stirring of
platelets is required for the expression of procoagulant
activity. It is possible that an efficient interaction of
platelets with collagen fibers requires stirring or that a
minimal shear stress is essential for the generation of a
pmocoagulant surface. The latter could be an important
biologic phenomenon, since circulating platelets in vivo
are also subject to shear stress. Since the flow regimen
of a solution stirred with a stirring bar consists of very
complex time-varying laminar flow streams, it is,
however, not possible to express procoagulant activities
as a function of the hydmodynamic force on the plate-
lets and to relate the shear force induced by stirring
with that acting on platelets in the circulation.
The data presented in Table I can be used to
quantitate the number of functional sites that partici-
pate in prothrombin and factor X activation at the
platelet surface. Since the coagulation factors were
present in saturating amounts, both activities were
measured at conditions approaching Vmas. For this
For personal use only. on November 3, 2014.  by guest    www.bloodjournal.org From 330 ROSING ET AL
calculation, the Vmax of prothrombin activation is taken
as 2,700 mol thrombin/min/mol factor Xa,’6 and the
Vmax of factor X activation as 500 mol factor Xa/
min/mol factor IXa,’4 and it is assumed that the
platelet-bound factor Xa-Va and factor IXa-Villa
complexes have the same activity as found in the model
systems. The latter assumption seems to be justified
because, so far, we have never found a procoagulant
surface (either from synthetic or platelet origin) that
gave Vmax values higher than those published ear-
lien.’5”6 The Vma. of prothmombin activation by factor
Xa in the presence of synthetic phospholipids and a
saturating concentration of factor Va is constant when
the amount of phosphatidylsenine present in the phos-
pholipid vesicles is varied between 2 and 30 mol%.38
The results of these calculations are presented in Table
4. Unstimulated and thrombin-stimulated platelets
have a low number of functional binding sites for the
prothrombin and factor X activating complexes (I ,000
to 3,000 per platelet). This number correlates very well
with the number of factor Va binding sites (2,000),
determined in a binding study under these conditions.4
We do not know, however, whether this correlation is
purely accidental or if it means that the factor Va
binding sites detected on unstimulated platelets are
functional sites that participate in prothrombin activa-
tion. For collagen plus thrombin stimulated platelets,
approximately 26,000 functional binding sites for the
prothrombinase complex and approximately 20,000
for the factor X activating complex are calculated. An
identical number of functional sites for pmothrombin
and factor X activation is to be expected when the
phosphatidylsenine exposed is an essential component
of the pmocoagulant site. (Also, the fact that the
collagen and thrombin requirements for generation of
platelet activity in prothmombin and factor X activa-
tion are the same supports this.)
It cannot be excluded that phosphatidylsenine is also
part of the procoagulant site (factor Xa-Va receptor)
at the surface of unstimulated platelets. This possibil-
ity is supported by the following observations: (a) A
small amount of phosphatidylserine (probably suffi-
cient to explain the low rate of prothrombin activation)
is determined in the outer monolayer of unstimulated
human platelets.9 This phosphatidylsenine can even be
present in domains with high density (see below). (b)
Prothrombin converting activity of unstimulated plate-
lets is abolished upon treatment with phospholipases.3’
(c) des(I-44) Factor Xa, a factor Xa derivative that
lacks ￿y-carboxyglutamyl residues, does not bind to the
platelet factor Xa receptor.4 We do not feel that the
experiments in which a monoclonal antibody against
negatively charged phospholipids does not block plate-
let prothrombin activation and factor Xa binding39 can
be used as an argument against phospholipid involve-
ment. This antibody only blocks prothmombin activa-
tion on synthetic phospholipid vesicles and does not
interact with platelet membrane preparations, for
which it can hardly be argued that negatively charged
phospholipids are absent. The authors suggest that the
phosphatidylserine in platelet membranes may be mela-
tively inaccessible to the antibody. Moreover, DahI-
back et al’￿#{176} recently reported a case with a polyclonal
lupus anticoagulant with specificity for negatively
charged phospholipids that inhibited platelet pro-
thrombinase activity.
Two other phenomena observed during our studies
on the properties of the procoagulant sites of platelets
need further discussion.
I . The time course of generation of the procoagu-
lant surface on collagen plus thrombin stimulated
platelets is different when pmothrombin and factor X
activation are measured at different coagulation factor
concentrations (Fig 4).
2. Phospholipase treatment of thrombin plus col-
lagen stimulated platelets more rapidly destroys the
procoagulant surface when this is measured at low
coagulation factor concentrations than when it is mea-
sured at high concentrations.
The results obtained with synthetic phospholipid
vesicles show that theme are remarkable differences in
phosphatidylsenine requirement in the assay systems
employed in the above-mentioned experiments. At low
concentrations of factor Xa-factom Va or factor IXa-
Table 4. Procoagulan t Sites on Human Plate let Membranes
Platelet Stimulator
Prothrombin
Activation
Factor X
Activation Factor Xa Factor Va
None
Thrombin
Thrombin + collagen
2.550
2.990
26, 120
920
1,240
19.000
<10
200-300’
ND
2,000-3,000t
ND
ND
The number of procoagulant sites per platelet is calculated with the formula: number of sites/platelet = vi V,￿ x 10 ￿ x Avogadro’s number/platelets
times 1 ￿ ‘ , in which v is the rate of prothrombin or factor X activation determined in the experiment presented in Fig 1 . and V,￿ is the maximal rate of
prothrombin activation’6 or factor X activation.’5 Data shown represent the functional sites per platelet (this paper).
ND, not determined.
#{149}Binding sites from reference 5.
fBinding sites from reference 4.
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factor VIlla, procoagulant surfaces containing low
amounts of phosphatidylsemine hardly stimulate pro-
thrombin and factor X activation. Optimal mates are
observed at 40 mol% phosphatidylsenine or higher. At
high concentrations of coagulation factors, the optimal
mol% phosphatidylsemine required is much lower (as
low as 2.5% for prothmombin activation at saturating
factor Xa and factor Va concentrations). Under these
conditions, pmocoagulant surfaces with low phosphati-
dylsenine still have an appreciable activity. Based on
these observations, it can be hypothesized that the
phosphatidylsemine exposed at the surface of collagen
plus thrombin stimulated platelets is not homoge-
neously distributed in the outer lipid leaflet of the
membrane bilayer. Domains with high phosphatidyl-
senine density, which rapidly appear at the surface of
stimulated platelets are measured at low coagulation
factor concentrations. Domains with low phosphatidyl-
semine density that appear slower can only be probed at
high coagulation factor concentrations. This would
also explain why the activity of the pmocoagulant
surface measured at low coagulation factor concentra-
tions is more sensitive to phospholipase treatment. It
has been shown that phosphatidylsenine monolayems, at
surface pressures found in the platelet membrane (34
dyne/cm’#{176}), are more rapidly degraded by phospholi-
pase A2 than monolayers of phosphatidylcholine.32’4’ It
is therefore likely that platelet membrane surface
areas containing high local phosphatidylsemine concen-
tmations are more susceptible to phospholipase A2 than
surface areas containing low phosphatidylsemine con-
centmations.
If such lateral phase separations occur in the outer
leaflet of the platelet plasma membrane after or during
platelet activation, it presumably requires other com-
ponents to induce or maintain them. An involvement of
extracellulam calcium in this process cannot be
excluded, but it is also possible that membrane proteins
participate in the properties of activated platelets to
produce at least two different lipid domains with
different phospholipid compositions.
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